Los Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-03-16 16:50:462021-03-16 16:52:33Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor
Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing. Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-02-24 03:50:002021-03-08 18:05:11Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
Los Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-01-07 04:06:002021-03-08 17:55:55Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]
Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515. If granted, […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2020-11-02 04:40:002021-03-08 21:43:36Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041
Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor
/in News /by Trethera SupportLos Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]
Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
/in News /by Trethera SupportLos Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing. Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
/in News /by Trethera SupportLos Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]
Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board
/in News /by Trethera SupportLos Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]
Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041
/in News /by Trethera SupportLos Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515. If granted, […]